NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE stock has decreased by 44.2% and is now trading at $0.4130.
View the best growth stocks for 2024 here.

NeuBase Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 149,100 shares, an increase of 85.2% from the March 15th total of 80,500 shares. Based on an average daily trading volume, of 233,400 shares, the days-to-cover ratio is presently 0.6 days. Approximately 4.9% of the company's shares are short sold.
View NeuBase Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NBSE earnings forecast.

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings data on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, topping the consensus estimate of ($4.60) by $0.40.

NeuBase Therapeutics's stock reverse split before market open on Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.